UPDATED Mar 26, 2024
Well rounded companies, with acceptable leverage, projected to deliver an ROE north of 20% in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
AZN | UK£107.42 | 5.7% | -3.8% | UK£166.5b | UK£127.74 | PE35.3x | E16.5% | 2.1% | ||
NOVN | CHF86.66 | 1.8% | 4.4% | CHF189.8b | CHF97.70 | PE24.5x | E9.4% | 3.8% | ||
ROG | CHF226.75 | -1.8% | -12.4% | CHF182.2b | CHF281.28 | PE15.7x | E8.3% | 4.2% | ||
600436 | CN¥230.88 | -2.0% | -18.0% | CN¥139.3b | CN¥295.86 | PE50x | E20.8% | 0.5% | ||
NATCOPHARM | ₹973.50 | 2.5% | 75.2% | ₹174.4b | ₹912.30 | PE13.6x | E14.4% | 1.0% |